Inhalation LABA-LAMA Composition With pH-Tuned COPD Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for chronic obstructive pulmonary disease (COPD) and asthma, while effective in relieving symptoms, face challenges due to potential side effects of corticosteroids and the need for multiple dosing, and there is a lack of effective anti-inflammatory treatments for acute exacerbations.
Innovation Solution
A pharmaceutical composition for inhalation comprising a combination of long-acting β2 agonists and long-acting muscarinic antagonists, optionally with high molecular weight hyaluronic acid, is developed to provide bronchodilation and anti-inflammatory effects, with potential inclusion of additional components like sodium chloride, EDTA, and cyclodextrins to enhance stability and delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If inhaled corticosteroids are used to treat COPD and asthma, then anti-inflammatory effects are achieved, but side effects occur and multiple dosing is required
Solution Approach 1:
The patent extracts and removes the corticosteroid component from the treatment regimen, relying solely on the combination of LABA and LAMA for both bronchodilation and anti-inflammatory effects. This eliminates side effects associated with corticosteroid use while maintaining therapeutic efficacy through the synergistic action of the two bronchodilators.
Solution Approach 2:
The patent employs long-acting formulations of LABA and LAMA that provide sustained therapeutic effects with single daily dosing, replacing the need for multiple corticosteroid doses. The long-acting nature of these medications allows for less frequent administration while maintaining reliable anti-inflammatory and bronchodilator effects.
2Reliability
If multiple medications are used to treat COPD and asthma, then therapeutic efficacy is improved, but dosing complexity increases
Solution Approach 1:
The patent combines LABA and LAMA into a single fixed-dose combination medication, merging two separate dosing regimens into one. This simplifies the dosing complexity while maintaining the therapeutic efficacy of both agents working synergistically to treat COPD and asthma.
Solution Approach 2:
The fixed-dose combination medication serves multiple functions simultaneously: it provides bronchodilation through both LABA and LAMA mechanisms, reduces dosing frequency, simplifies the treatment regimen, and eliminates the need for separate administration of multiple medications, thereby achieving multi-functionality in a single product.
3Duration of action of moving object
If long-acting bronchodilators are used, then symptom relief is prolonged, but the need for combination therapy with corticosteroids increases
Solution Approach 1:
The patent merges LABA and LAMA into a single combination therapy that provides prolonged bronchodilation through dual mechanisms of action. This combination eliminates the perceived need for additional corticosteroid therapy by delivering sustained symptom relief and addressing inflammatory components through the synergistic effects of the two long-acting bronchodilators.
Solution Approach 2:
The fixed-dose combination of LABA and LAMA acts as a composite therapeutic approach, integrating two different pharmacological mechanisms (beta-2 adrenergic agonism and muscarinic antagonism) into a single formulation. This composite therapy provides prolonged bronchodilation and reduces the need for additional corticosteroid medications.
Data Source
AI summary
Disclosed is a pharmaceutical composition for inhalation, comprising long-acting β2 agonist and long-acting muscarinic antagonist. The long-acting β2 agonist comprises olodaterol; or long-acting β2 agonist comprises arformoterol, and the pH of the composition is 3.5-5.5; or long-acting β2 agonist comprises indacaterol, and the pH of the composition is 2.5-4.5; or the long-acting muscarinic antagonist comprises revefenacin, and the pH of the composition is 3.5-5.5; or the long-acting muscarinic antagonist comprises glycopyrronium bromide, and the pH of the composition is 2.5-4.5; or the long-acting muscarinic antagonist comprises tiotropium bromide, and the pH of the composition is 2.0-4.0. Disclosed is a use of the pharmaceutical composition for inhalation for the preventing or treating of respiratory diseases such as asthma, chronic obstructive pulmonary disease, and the like.